Drug Trial Radar · NCT06137118
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
255
Planned (sponsor's estimate)
Start
Dec 29, 2023
Primary completion
Jan 6, 2028
Study completion Aug 10, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimization study of surovatamig (AZD0486) to evaluate the safety, tolerability, and efficacy of surovatamig (AZD0486) monotherapy in participants with R/R B ALL. The study will consist of 4 parts. Part A: monotherapy dose escalation in 3L+ B-ALL. Part B: dose optimization in 3L+ B-ALL. Part C: Dose expansion in 3L+ B-ALL. Part D: Dose optimization and efficacy expansion in R/R B-ALL (2L+)
Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
Interventions
SurovatamigDrug
Investigational Product administered via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Frequency of DLTsTime frame: Up to 28 days
- Parts A & B: Safety Evaluation of AZD0486Time frame: From signing of informed consent through data cutoff, up to 57 months
- Parts B & C: Rate of CR within 3 cyclesTime frame: Up to three cycles of 28 days each
- Part D: CR/CRh within 3 cyclesTime frame: Up to three cycles of 28 days each
Locations
83 sites in 13 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama · Withdrawn
Research Site
Duarte, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Palo Alto, California · Recruiting
Research Site
Tampa, Florida · Recruiting
Research Site
Atlanta, Georgia · Recruiting
Research Site
Chicago, Illinois · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Richmond, Virginia · Recruiting
Research Site
Seattle, Washington · Withdrawn
Research Site
Milwaukee, Wisconsin · Recruiting
Research Site
Melbourne, Australia · Withdrawn
Research Site
Porto Alegre, Brazil · Suspended
Research Site
São Paulo, Brazil · Suspended
Research Site
São Paulo, Brazil · Suspended
Research Site
Toronto, Ontario, Canada · Recruiting
Research Site
Montreal, Quebec, Canada · Withdrawn
Research Site
Montreal, Quebec, Canada · Withdrawn
Research Site
Changsha, China · Recruiting
Research Site
Chengdu, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Hangzhou, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Nanjing, China · Recruiting
Research Site
Suzhou, China · Recruiting
Research Site
Tianjin, China · Recruiting
Research Site
Zhengzhou, China · Recruiting
Research Site
Caen, France · Suspended
Research Site
Marseille, France · Recruiting
Research Site
Nantes, France · Suspended
Research Site
Paris, France · Recruiting
Research Site
Pierre-Bénite, France · Suspended
Research Site
Toulouse, France · Suspended
Research Site
Berlin, Germany · Not yet recruiting
Research Site
Cologne, Germany · Recruiting
Research Site
Düsseldorf, Germany · Recruiting
Research Site
Essen, Germany · Withdrawn
Research Site
Frankfurt, Germany · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.